Edition:
United States

Emergent BioSolutions Inc (EBS)

EBS on New York Consolidated

29.44USD
20 Jan 2017
Change (% chg)

$0.10 (+0.34%)
Prev Close
$29.34
Open
$29.32
Day's High
$29.52
Day's Low
$28.91
Volume
606,982
Avg. Vol
508,225
52-wk High
$44.38
52-wk Low
$24.47

EBS

Chart for EBS

About

Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of... (more)

Overall

Beta: 1.07
Market Cap(Mil.): $1,192.26
Shares Outstanding(Mil.): 40.50
Dividend: --
Yield (%): --

Financials

  EBS Industry Sector
P/E (TTM): 20.82 44.85 30.38
EPS (TTM): 1.41 -- --
ROI: 7.44 -1.38 14.86
ROE: 11.03 -1.07 16.28

BRIEF-Aptevo Therapeutics receives $20 mln payment from Emergent Biosolutions

* Aptevo Therapeutics receives $20 million payment from Emergent Biosolutions

Jan 13 2017

BRIEF-Emergent Biosolutions announces preliminary 2016 financial results

* Emergent Biosolutions announces preliminary 2016 financial results and provides 2017 financial outlook

Jan 09 2017

BRIEF-Emergent Biosolutions Q3 adjusted EPS $0.58 from continuing operations

* Emergent biosolutions reports third quarter and nine months 2016 financial results

Nov 07 2016

BRIEF-Emergent biosolutions provides update on biothrax procurement contract and discussions with CDC

* Emergent Biosolutions provides update on status of Biothrax procurement contract and discussions with CDC

Sep 30 2016

BRIEF-Emergent awarded BARDA contract for advanced development of NuThrax

* Awarded BARDA contract for advanced development and delivery of NuThrax, a next generation anthrax vaccine, valued at up to $1.6 billion

Sep 30 2016

BRIEF-Emergent Biosolutions gets FDA approval for large-scale manufacturing of Biothrax in building 55

* Emergent Biosolutions receives FDA approval for large-scale manufacturing of Biothrax in building 55 Source text for Eikon: Further company coverage:

Aug 15 2016

BRIEF-Emergent announces conversion rate adjustment to 2.875% convertible senior notes

* Emergent biosolutions announces conversion rate adjustment to 2.875% convertible senior notes due 2021 following spin-off of aptevo therapeutics Source text for Eikon: Further company coverage:

Aug 12 2016

BRIEF-Emergent BioSolutions Q2 GAAP loss per share $0.27

* Emergent BioSolutions reports second quarter and six months 2016 financial results

Aug 04 2016

Competitors

Earnings vs. Estimates